Skip to main content

Table 3 On-going immunotherapy clinical trials

From: From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

Treatment type Phase Target N Additional therapy Stage Identifier
Chimeric antibody I,II Ensituximab 116 None Metastatic NCT01040000a
DNA vaccine I VEGFR-2 72 None Metastatic NCT01486329a
Fungal vector vaccine II RAS 176 Gemcitabine Resected NCT00300950a
Viral vector vaccine I Small Pox Virus 36 None Metastatic NCT00574977a
Allogeneic vaccine I CEA 48 GM-CSF Metastatic NCT00028496a
I Donor Lymphocyte 37 None Metastatic NCT00161187a
I Dendritic cells 12 Poly-ICLC Unresectable NCT01677962
II GM-CSF 60 Cetuximab + Cyclophosphamide Metastatic NCT00305760a
II GVAX 56 None Metastatic NCT00389610
II GVAX 87 Cyclophosphamide Resectable NCT0072744
II GVAX 19 Cyclophosphamide, Radiation, FOLFIRINOX Resected NCT01595321
II GVAX +/- Mesothelin 93 Cyclophosphamide Metastatic NCT01417000
II GVAX +/- Mesothelin 240 Gemcitabine, Capecitabine, 5-FU, Irinotecan, Erlotinib or Cyclophosphamide Metastatic NCT02004262
II IFN-α + GM-CSF 14 Cyclophosphamide Metastatic NCT00002773a
III Virulizin 400 Gemcitabine +/- 5-FU Metastatic NCT00040092a
Autologous vaccine I CEA 24 None Metastatic NCT00004604a
I CEA 14 None Metastatic NCT00027534a
I CEA 24 Denileukin Diftitox Metastatic NCT00128622a
II CEA 48 IL-2 Metastatic NCT01723306
I Dendritic Cells 2 Gemcitabine + Stereotactic Radiosurgery Metastatic NCT00547144a
II KLH 35 Radiation Metastatic NCT00868114
Immunotherapy I B7-H3 93 none All NCT01391143
I CD40 10 Gemcitabine + nab-paclitaxel Metastatic NCT02588443
I CD40 10 Gemcitabine resected NCT01456585a
II CTLA-4 82 None Metastatic NCT00112580a
I CTLA-4 37 Gemcitabine Metastatic NCT00556023a
I CTLA-4 28 Gemcitabine Metastatic NCT01473940
II CTLA-4 + GVAX 92 FOLFIRINOX Metastatic NCT01896869
II IDO 98 Gemcitabine + nab-paclitaxel metastatic NCT02077881
I IL-1-Ra 13 FOLFIRINOX Metastatic NCT02021422
I/II PD-1 56 Capecitabine + Radiation Resectable and Borderline Resectable NCT02305186
I PD-L1 1038 none All NCT01693562
Peptide vaccine I,II Alpha (1, 3) galactosyltransferase 7 None Metastatic NCT00255827a
III Alpha (1, 3) galactosyltransferase 280 FOLFIRINOX Locally Advanced NCT01836432
III Alpha (1,3) galactosyltransferase 722 Gemcitabine, 5-FU, radiation Resected NCT01072981
I,II CEA 28 None Metastatic NCT00529984a
I CEA + MUC1 18 None Unresectable NCT00669734
I hCG-β 36 None Metastatic NCT00648102a
I hCG-β 48 None Metastatic NCT00709462a
I Heat Shock Protein 16 None Resected NCT00003025a
I/II Hedgehog 122 Gemcitabine Metastatic NCT01130142a
I Hedgehog 21 FOLFIRINOX Unresectable NCT01383538
I MUC1 25 None Resected or Locally Advanced NCT00008099a
I/II MUC5AC 90 Gemcitabine + nab-paclitaxel Unresectable NCT01834235
I P53 12 None Unresectable NCT01191684a
II P53 + RAS 70 IL-2 Metastatic NCT00019084a
I RAS 7 None Metastatic NCT00006387a
I RAS 33 None Metastatic NCT00019006a
III Telomerase 1110 Capecitabine + Gemcitabine Metastatic NCT00425360a
I TGF-β 168 Gemcitabine Resectable and unresectable NCT01373164
I Trophoblast glycoprotein 44 None Metastatic NCT00056537a
I/II VEGF 17 Gemcitabine Unresectable NCT00655785a
I VEGFR-2 21 Gemcitabine Metastatic NCT00622622a
  1. 5-FU 5-flurouracil, CEA Carcinoembryonic antigen, CTLA-4 Cytotoxic T-lymphocyte associated protein-4, FOLFIRINOX folinic acid, fluorouracil, irinotecan, oxaliplatin, GM-CSF granulocyte macrophage colony stimulating factor, hCG Human chorionic gonadotropin, IDO indoleamine 2,3-dioxygenase, IFN interferon, IL-2 interleukin-2, KLH keyhole limpet hemocyanin, MUC mucin, N number, PD programmed death, PD-L programmed death ligand, Poly-ICLC carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA, TGF Transforming growth factor, VEGF Vascular endothelial growth factor, VEGF-R Vascular endothelial growth factor receptor
  2. aStudy listed as complete but results not published